drugset
Drugs / Double Mutant Heat-Labile Toxin
last change May 2020 re-read 3 minutes ago

Double Mutant Heat-Labile Toxin

also known as dmLT · LTR192G/L211A

Vaccine

Developed for
gastroenteritis
Investigated by
National Institute of Allergy and Infectious Diseases (NIAID)

Trials 1

today NCT02531685 · Ph 1
20172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT02531685 Jun 2016 → May 2020 gastroenteritis National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Double Mutant Heat-Labile Toxin “Double Mutant Heat-Labile Toxin LTR192G/L211A (dmLT)” NCT02531685 ↗
Known as dmLT ClinicalTrials.gov intervention name — accepted as the source's own label NCT02531685 ↗
Known as LTR192G/L211A “Double Mutant Heat-Labile Toxin LTR192G/L211A (dmLT)” NCT02531685 ↗
Modality Vaccine “an Enterotoxigenic Escherichia coli (ETEC) candidate vaccine, attenuated recombinant Double Mutant Heat-Labile Toxin (dmLT) from ETEC” NCT02531685 ↗